5004-07-9

Basic information

• Product Name: 4-(1-Pyrrolidinyl)piperidine
• Synonyms: 4-PYRROLIDINOPIPERIDINE;4-PYRROLIDIN-1-YL-PIPERIDINE;4-(1-PYRROLIDINYL)PIPERIDINE;4-(1-PYRROLIDINYL)PIPERIDINE 2HCL;AKOS BB-9181;4-(1-PYRROLIDINYL)PIPERIDINE 95%;4-(1-Pyrrolidinyl)Piperidine99%;4-PYRROLIDIN-1-YL-PIPERIDINE >98%
• CAS NO: 5004-07-9
• Molecular Formula: C9H18N2
• Molecular Weight: 154.25
• EINECS: 225-676-6
• Product Categories: Amines and Anilines;Piperidine;Piperidine Series;Building Blocks;Heterocyclic Building Blocks;Piperidines
• Mol File: 5004-07-9.mol

Chemical Properties

• Melting Point: 53-56 °C(lit.)
• Boiling Point: 228.8 °C at 760 mmHg
• Flash Point: 92 °C
• Appearance: White/Crystals
• Density: 0.989 g/cm³
• Vapor Pressure: 0.011mmHg at 25°C
• Refractive Index: 1.591
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• Solubility: soluble in Methanol
• PKA: 10.32±0.20(Predicted)
• Sensitive: Air Sensitive
• CAS DataBase Reference: 4-(1-Pyrrolidinyl)piperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(1-Pyrrolidinyl)piperidine(5004-07-9)
• EPA Substance Registry System: 4-(1-Pyrrolidinyl)piperidine(5004-07-9)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36-37/39
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 5004-07-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(1-Pyrrolidinyl)piperidine is used as a synthetic building block for the creation of Monensin A esters, which are antibiotics. These antibiotics are utilized in the treatment of various bacterial infections, highlighting the importance of 4-pypp in the development of pharmaceuticals.
Used in Chemical Research:
In the field of chemical research, 4-(1-Pyrrolidinyl)piperidine serves as a subject for the study of its chemical properties and behavior. Its formation of Hofmann type complexes, as well as the analysis of its FT-IR and Raman spectra, contribute to the understanding of its structure and potential applications in various chemical processes.

InChI:InChI=1/C9H8N2/c1-2-8-11(7-1)9-3-5-10-6-4-9/h1-8H

Upstream product

• 4876-57-7 1-benzyl-4-pyrrolidin-1-yl-piperidine 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 902837-26-7 4-pyrrolidinylpiperidine-1-carboxylic acid tert-butyl ester 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 40064-34-4 piperidine-4,4-diol hydrochloride 

Downstream Products

• 873225-54-8 [4-(4-hydroxy-pyrimidin-2-ylamino)-phenyl]-(4-pyrrolidin-1-yl-piperidin-1-yl)-methanone 
• 873225-46-8 IKK Inhibitor VII 
• 863029-99-6 Balamapimod 
• 863030-24-4 4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-{3-[4-(1-pyrrolidinyl)-1-piperidinyl]propoxy}-3-quinolinecarbonitrile 

Relevant articles and documents

QUINOLINE DERIVATIVES AS SMO INHIBITORS

Disclosed are quinoline derivatives as hedgehog pathway inhibitors, especially as SMO inhibitors. Compounds of the present invention can be used in treating diseases relating to hedgehog pathway including cancer.

Pyrimidine or pyridine pyridine ketone compound and its preparation method and application (by machine translation)

The invention discloses a kind of type I of the pyrimidine or pyridine pyridine ketone compound and its preparation and application, which belongs to the technical field of pharmaceutical preparation. The compounds have high-efficient and selectively inhibit the cell cycle dependent kinases (Cdks) CDK4 and CDK6 active, and then by inhibiting CDK4/CDK6 prevent tumor cell division. Therefore, the compounds of this invention can be used for CDK4 and CDK6 the involved in cell cycle control disorders result in various diseases, especially suitable for the treatment of malignant tumors. (by machine translation)

Design and optimization of quinazoline derivatives as melanin concentrating hormone receptor 1 (MCHR1) antagonists

Melanin concentrating hormone (MCH) is an important mediator of energy homeostasis and plays a role in metabolic and CNS disorders. The modeling-supported design, synthesis and multi-parameter optimization (biological activity, solubility, metabolic stability, hERG) of novel quinazoline derivatives as MCHR1 antagonists are described. The in vivo proof of principle for weight loss with a lead compound from this series is exemplified. Clusters of refined hMCHR1 homology models derived from the X-ray structure of the β2-adrenergic receptor, including extracellular loops, were developed and used to guide the design.

Synthesis of substituted 4(Z)-(methoxyimino)pentyl-1-piperidines as dual NK1/NK2 inhibitors

The NK1 and NK2 receptor activity of a series of 5-[(3,5-bis(trifluoromethyl)phenyl)methoxy]-3-(3,4-dichlorophenyl)-4(Z)- (methoxyimino)pentyl-1-piperidines was evaluated. Compounds 11d, 11e, 11f, 12a, and 12k were found to be our most potent inhibitors.